Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Beigene Ltd ADR (NQ: BGNE ) 198.59 +1.31 (+0.66%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 19, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 194,614 Open 198.00 Bid (Size) 195.00 (2) Ask (Size) 208.10 (1) Prev. Close 197.28 Today's Range 197.73 - 200.98 52wk Range 126.97 - 215.00 Shares Outstanding 1,211,067,023 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Chinese Biotech BeiGene Labeled 'Unique Investment' As Analyst Confident In Lead Cancer Drug September 18, 2024 JMP Securities has initiated coverage on BeiGene highlighting the Chinese biotech company as a 'unique investment opportunity.' The firm's leading drug, Brukinsa (zanubrutinib), is emerging in the... Via Benzinga What Analysts Are Saying About BeiGene Stock September 18, 2024 Via Benzinga Performance YTD +12.20% +12.20% 1 Month +2.26% +2.26% 3 Month +27.68% +27.68% 6 Month +21.31% +21.31% 1 Year +2.98% +2.98% More News Read More Oxford Industries Reports Weak Results, Joins Viper Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session September 12, 2024 Via Benzinga Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket September 12, 2024 Via Benzinga Top 2 Health Care Stocks That May Plunge In August August 26, 2024 Via Benzinga BeiGene Announces Updates to Commercial Leadership Team September 09, 2024 From BeiGene, Ltd. Via Business Wire Innovent Bio hopes for plus-sized profits from obesity drug September 06, 2024 Via Benzinga Topics Retirement Exposures Pension Week In Review: UCB Sells China Drug Portfolio To CBC For $680 Million August 31, 2024 Via Talk Markets BeiGene to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference August 28, 2024 From BeiGene, Ltd. Via Business Wire BeiGene’s BGB-16673 Receives U.S. FDA Fast Track Designation for CLL/SLL August 26, 2024 From BeiGene, Ltd. Via Business Wire Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer August 23, 2024 Via Benzinga Exposures Product Safety BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates August 07, 2024 From BeiGene Via Business Wire Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal July 27, 2024 Via Talk Markets BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World July 23, 2024 From BeiGene, Ltd. Via Business Wire AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now? July 22, 2024 Via The Motley Fool BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer July 18, 2024 From BeiGene, Ltd. Via Business Wire Moderna And Walgreens Boots Alliance Were Among The 10 Biggest Large Cap Losers Last Week (June 23 - June 29): Are These In Your Portfolio? June 30, 2024 Via Benzinga What's Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday? June 17, 2024 Via Benzinga Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare June 15, 2024 Via Talk Markets BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024 June 14, 2024 From BeiGene, Ltd. Via Business Wire BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference June 04, 2024 From BeiGene, Ltd. Via Business Wire 7 Large-Cap Stocks That Can Jump 50% By 2025 May 29, 2024 Via InvestorPlace Lululemon Athletica Was Among The Worst-Performing Stocks Last Week (May 19-May 26, 2024): Are These 10 Large-Cap Stock Losers In Your Portfolio? May 26, 2024 Via Benzinga Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings May 25, 2024 Via Talk Markets BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL May 24, 2024 From BeiGene, Ltd. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
